Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
Bristol-Myers Squibb Company (NYSE:BMY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 3, Arcus Biosciences announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE:BMY), where Arcus’s investigational kidney cancer drug, casdatifan, will be added to Bristol-Myers’s ongoing Phase 1/2 ROSETTA RCC-208 trial. The trial focuses on […]
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?
Bristol-Myers Squibb (NYSE:BMY) has been added to the Russell 1000 Value Defensive and Russell 1000 Defensive Indexes. At the same time, the company has been removed from several growth-focused Russell benchmarks. This reclassification marks a shift in how major indexes group Bristol-Myers Squibb within the market. Bristol-Myers Squibb, a large US-based pharmaceutical company, now sits firmly in the value and defensive camp within the Russell index family. For investors who follow NYSE:BMY,...
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company (NYSE:BMY) is one of the best low-priced pharma stocks on this list. TheFly reported on June 15 that RBC Capital analyst Trung Huynh noted that the proposed changes to the Medicare Drug Price Negotiation Program could introduce potential […]
The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.
June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according to letters seen by Reuters.
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.56, marking a +1.81% move from the previous day.
AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.
At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb: ... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target
Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination of a depressed valuation and a commercial product already gaining ground.
Looking back at past stock picks is important because it helps investors understand what worked, what didn’t, and why. The insurance stock is down 19% over the past year but has gained 8% over the past month.
(Bloomberg) -- At the Hirslanden clinic overlooking Switzerland’s picturesque Lake Lucerne, prostate cancer patient Jörg Pegelow lies on a reclining chair as a doctor wearing two sets of gloves — one made with lead — injects a saline solution laced with a radioactive drug into a vein in his arm.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapOracle Cut 21,000 Jobs in 12 Months, Says AI Replaced
At 64, with $1.1 million in a Traditional IRA, tax-deferred cash flow is the point. With the 10-year Treasury at 4.50% and the 30-year at 4.94%, dividend yields have to earn their seat. The 10-year has swung between 4.43% and 4.56% in June alone, and that yield volatility is exactly what forced me to re-stack ... 64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
Bristol Myers Squibb’s board previously declared a quarterly dividend of US$0.63 per share on its common stock, payable on August 3, 2026, to shareholders of record as of July 2, 2026. This dividend decision comes as the company works to address upcoming patent expirations by advancing a broad pipeline that includes 50 compounds and multiple new medicines targeted for launch by 2030. We’ll now examine how this affirmed dividend, alongside Bristol Myers Squibb’s expanding pipeline, shapes the...
The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.53, representing a +1.52% change from its previous close.
Bristol-Myers Squibb Company (NYSE:BMY) is among the Best Pharmaceutical Stocks. On June 2, Bristol-Myers Squibb Company (NYSE:BMY) and SystImmune announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical, reported interim Phase 3 data. It showed that izalontamab brengitecan had statistically significant progress in overall survival and progression-free survival in advanced triple-negative breast cancer and esophageal squamous […]
CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX's huge public offering didn't hurt either.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
